These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18820995)

  • 1. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.
    Raya JM; Arenillas L; Domingo A; Bellosillo B; Gutiérrez G; Luño E; Piñán MA; Barbón M; Pérez-Sirvent ML; Muruzábal MJ; Yánez L; García L; Lemes A; Navarro JT; Elosegi A; Cortés MA; Villegas A; Durán MA; Ardanaz M; Florensa L;
    Int J Hematol; 2008 Nov; 88(4):387-395. PubMed ID: 18820995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
    Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings.
    Gurevich I; Luthra R; Konoplev SN; Yin CC; Medeiros LJ; Lin P
    Am J Clin Pathol; 2011 Mar; 135(3):398-403. PubMed ID: 21350094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Remacha AF; Nomdedéu JF; Puget G; Estivill C; Sarda MP; Canals C; Aventin A
    Haematologica; 2006 May; 91(5):719-20. PubMed ID: 16670082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
    Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
    Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Malcovati L; Della Porta MG; Pietra D; Boveri E; Pellagatti A; Gallì A; Travaglino E; Brisci A; Rumi E; Passamonti F; Invernizzi R; Cremonesi L; Boultwood J; Wainscoat JS; Hellström-Lindberg E; Cazzola M
    Blood; 2009 Oct; 114(17):3538-45. PubMed ID: 19692701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.
    Broseus J; Florensa L; Zipperer E; Schnittger S; Malcovati L; Richebourg S; Lippert E; Cermak J; Evans J; Mounier M; Raya JM; Bailly F; Gattermann N; Haferlach T; Garand R; Allou K; Besses C; Germing U; Haferlach C; Travaglino E; Luno E; Pinan MA; Arenillas L; Rozman M; Perez Sirvent ML; Favre B; Guy J; Alonso E; Ahwij N; Jerez A; Hermouet S; Maynadié M; Cazzola M; Girodon F
    Haematologica; 2012 Jul; 97(7):1036-41. PubMed ID: 22532522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of refractory anemia with ring sideroblasts associated with thrombocytosis from pre-existing refractory anemia with ring sideroblasts through acquisition of Jak2 V617F mutation.
    Lu CM; Zhou L; Wang E; Feng S; Sebastian S; Behler C
    Leuk Lymphoma; 2011 Dec; 52(12):2405-7. PubMed ID: 21806348
    [No Abstract]   [Full Text] [Related]  

  • 9. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
    Broséus J; Alpermann T; Wulfert M; Florensa Brichs L; Jeromin S; Lippert E; Rozman M; Lifermann F; Grossmann V; Haferlach T; Germing U; Luño E; Girodon F; Schnittger S;
    Leukemia; 2013 Sep; 27(9):1826-31. PubMed ID: 23594705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
    Patnaik MM; Tefferi A
    Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
    Ziarkiewicz M; Dwilewicz-Trojaczek J; Pastwińska A; Chmarzyńska E; Paszkowska-Kowalewska M; Koperski Ł; Jędrzejczak WW; Ziarkiewicz-Wróblewska B
    Pol J Pathol; 2010; 61(2):105-9. PubMed ID: 20924996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and biological features in refractory anemia with ringed sideroblasts with fluctuant platelet counts].
    Ji O; Shen Q; Lin L; Zhang YC; Ji JM; Wu Y; Chen JY; Zhu GR; Kong XT; Xia W; Jiang PJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1036-41. PubMed ID: 20723324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
    Szpurka H; Tiu R; Murugesan G; Aboudola S; Hsi ED; Theil KS; Sekeres MA; Maciejewski JP
    Blood; 2006 Oct; 108(7):2173-81. PubMed ID: 16741247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: case report and literature review.
    Găman M; Vlădăreanu AM; Onisai M
    Rom J Morphol Embryol; 2012; 53(3):645-50. PubMed ID: 22990561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
    Atallah E; Nussenzveig R; Yin CC; Bueso-Ramos C; Tam C; Manshouri T; Pierce S; Kantarjian H; Verstovsek S
    Leukemia; 2008 Jun; 22(6):1295-8. PubMed ID: 18059483
    [No Abstract]   [Full Text] [Related]  

  • 16. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Renneville A; Quesnel B; Charpentier A; Terriou L; Crinquette A; Laï JL; Cossement C; Lionne-Huyghe P; Rose C; Bauters F; Preudhomme C
    Leukemia; 2006 Nov; 20(11):2067-70. PubMed ID: 16990759
    [No Abstract]   [Full Text] [Related]  

  • 17. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
    Steensma DP; Caudill JS; Pardanani A; McClure RF; Lasho TL; Tefferi A
    Haematologica; 2006 Dec; 91(12 Suppl):ECR57. PubMed ID: 17194663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable.
    Gattermann N; Billiet J; Kronenwett R; Zipperer E; Germing U; Nollet F; Criel A; Selleslag D
    Blood; 2007 Feb; 109(3):1334-5. PubMed ID: 17244688
    [No Abstract]   [Full Text] [Related]  

  • 19. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?
    Wardrop D; Steensma DP
    Br J Haematol; 2009 Mar; 144(6):809-17. PubMed ID: 19120370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.
    Wang SA; Hasserjian RP; Loew JM; Sechman EV; Jones D; Hao S; Liu Q; Zhao W; Mehdi M; Galili N; Woda B; Raza A
    Leukemia; 2006 Sep; 20(9):1641-4. PubMed ID: 16871284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.